Investigation Overview
October 19, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Zafgen Inc (NASDAQ:ZFGN) shares over potential securities laws violations by Zafgen and certain of its directors and officers in connection certain financial statements was announced.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Zafgen Inc (NASDAQ:ZFGN) concerning whether a series of statements by Zafgen regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On October 14, 2015, Zafgen Inc issued a statement acknowledging the death of a patient in its ongoing double-blind, randomized, placebo-controlled Phase 3 bestPWS study of beloranib in Prader-Willi Syndrome.
Shares of Zafgen Inc (NASDAQ:ZFGN) declined to as low as $10.90 per share on October 14, 2015, respectively $10.06 per share on October 16, 2015.